This situation with a Vanderbilt chemistry graduate student seems bad (emphasis mine):
The standard drugs used for AML will not be sufficient in my case. Fortunately, there is a drug in a Vanderbilt clinical trial that is available (called midostaurin) that has been shown to help patients with my particular mutation to achieve remission. However, moving forward, the Vanderbilt insurance company for graduate students has decided that they will not pay for ANY care (hospital stay and standard care) associated with this clinical trial.
To be clear, the clinical trial is funded by a pharmaceutical company and does not need to be covered by the insurance company. The insurance company solely has to pay for the ROUTINE STANDARD care that goes along with the clinical trial.More details here. Best wishes to Mr. Kantor.
UPDATE: The insurance company decided to cover him. Hooray!